CD8A and neoplasm: We therefore transferred purified and activated splenic CD45.1+ CD8+ T cells from transgenic TCR (P14) mice recognizing the LCMV gp33 peptide [29] into tumor-bearing mice followed by vehicle or 5-NL treatment (Supplementary Fig. 3B).